AAV5-PBGD gene therapy

N/A

Report date: 2023/10/26 16:01:46

Base Information

Drug NameAAV5-PBGD gene therapy
Drug Alias NameAMT-021rAAV2/5-PBGDAAV5-AAT-PBGDAMT-020
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector
Mechanisms of ActionGene transferencePorphobilinogen deaminase stimulants
TargetsPorphobilinogen deaminase
Therapy Area/IndicationsPorphyria, Acute Intermittent
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySpain
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesDigna Biotech SlUniversity Of Navarra
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesDigna Biotech SlUniversity Of Navarra
Active IndicationsN/A
Inactive IndicationsPorphyria, Acute Intermittent

Other Information

ATC CodeN/A
Related LinksN/A